Silence Therapeutics plc (SLN)
- Previous Close
4.0100 - Open
4.0100 - Bid 3.1700 x 200
- Ask 5.3800 x 200
- Day's Range
4.0100 - 4.4200 - 52 Week Range
1.9700 - 24.3800 - Volume
95,898 - Avg. Volume
235,962 - Market Cap (intraday)
207.105M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5300 - Earnings Date Aug 15, 2025 - Aug 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.80
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
www.silence-therapeutics.comRecent News: SLN
View More
Performance Overview: SLN
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLN
View MoreValuation Measures
Market Cap
137.44M
Enterprise Value
966.12k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.81
Price/Book (mrq)
--
Enterprise Value/Revenue
0.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-104.74%
Return on Assets (ttm)
-19.24%
Return on Equity (ttm)
-58.08%
Revenue (ttm)
43.26M
Net Income Avi to Common (ttm)
-45.31M
Diluted EPS (ttm)
-1.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
147.33M
Total Debt/Equity (mrq)
0.09%
Levered Free Cash Flow (ttm)
-25.37M